Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ticlopidine: a new platelet aggregation inhibitor.

M K Ito1, A R Smith, M L Lee

  • 1San Diego Program, School of Pharmacy, University of the Pacific, Stockton, CA.

Clinical Pharmacy
|July 1, 1992
PubMed
Summary

Ticlopidine effectively prevents stroke and vascular events by inhibiting platelet aggregation. While effective, serious side effects like neutropenia mean it

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial behaviour of sheep during the neonatal period: Preliminary study on the influence of shelter.

Animal : an international journal of animal bioscience·2021
Same author

Invited Review - A 5-year update on epigenome-wide association studies of DNA modifications in Alzheimer's disease: progress, practicalities and promise.

Neuropathology and applied neurobiology·2020
Same author

Social anxiety and age are associated with neural response to social evaluation during adolescence.

Developmental cognitive neuroscience·2020
Same author

First Results from CUORE: A Search for Lepton Number Violation via 0νββ Decay of ^{130}Te.

Physical review letters·2018
Same author

Outcomes following autologous hematopoietic stem cell transplant for patients with relapsed Wilms' tumor: a CIBMTR retrospective analysis.

Bone marrow transplantation·2017
Same author

Psychological Outcomes of Living Liver Donors From a Multicenter Prospective Study: Results From the Adult-to-Adult Living Donor Liver Transplantation Cohort Study2 (A2ALL-2).

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016

Area of Science:

  • Pharmacology and Clinical Medicine
  • Cardiovascular Thrombosis Prevention

Background:

  • Ticlopidine is an antiplatelet agent with established efficacy.
  • Its mechanism involves inhibiting adenosine diphosphate-induced platelet aggregation.

Purpose of the Study:

  • To review the chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of ticlopidine.
  • To evaluate ticlopidine's role in preventing thrombotic events.

Main Methods:

  • Review of existing literature including multicenter, randomized, double-blind trials.
  • Analysis of clinical data on efficacy and adverse events.

Main Results:

  • Ticlopidine demonstrated superior efficacy over aspirin and placebo in preventing stroke and myocardial infarction.
  • It also showed benefits in preventing aortocoronary bypass graft occlusion and diabetic microangiopathy.
  • The most serious adverse effect is neutropenia (approx. 1%), with gastrointestinal issues being common.

Conclusions:

  • Ticlopidine is indicated for reducing thrombotic stroke risk in specific patient populations.
  • It serves as an alternative for primary and secondary stroke prevention.
  • Due to risks and cost, ticlopidine is reserved for patients intolerant or unresponsive to aspirin.

Related Experiment Videos